The research team, led by Loren K. Barcenas of the Department of Health Behavior and senior author Leah Frerichs, conducted a systematic review of published systematic reviews, meta-analyses, and scoping reviews, following the PRISMA reporting guidelines that govern how evidence syntheses are identified, screened, and reported. The investigators searched three major biomedical databases, PubMed, Embase, and the Cumulative Index in Nursing and Allied Health Literature, for reviews published since 2014 that examined opioid impacts on pediatric populations. Two reviewers independently screened candidate articles and evaluated the methodological quality of each included review using the 11-item Joanna Briggs Institute criteria checklist, a standardized tool for judging how rigorously a review was conducted. From that process, twenty studies met the inclusion criteria and formed the evidentiary backbone of the umbrella review.

One sober methodological finding deserves attention before the substance: the average quality score of the included reviews was just 5.75 out of 11. That number signals to readers that while the collective evidence is broad, much of it rests on reviews with methodological limitations, whether in their search strategies, their assessment of individual studies, or their handling of bias. The authors are transparent about this constraint, and it frames the review’s conclusions as a map of what is known, and what is known less well, rather than a set of definitive effect estimates. For a field in which research funding and policy attention have historically flowed toward adult populations, that uneven evidence base is itself part of the story.

What the twenty reviews did document falls into four major outcome categories: physical health, neurodevelopment, psychosocial outcomes, and caregiving disruptions. The physical health effects are most visible in newborns. Infants exposed to opioids in the womb can develop neonatal abstinence syndrome, increasingly called neonatal opioid withdrawal syndrome, a constellation of withdrawal symptoms that can include irritability, feeding difficulties, tremors, and the need for extended hospitalization and pharmacologic treatment. These conditions have become a barometer of the crisis’s reach into delivery wards, and the umbrella review confirms that infants with prenatal opioid exposure are the most extensively studied pediatric group in the literature, with a substantial body of work documenting their immediate clinical course and early health trajectories.

Beyond the neonatal period, the evidence turns to neurodevelopment. Reviews synthesized in the analysis examined whether prenatal opioid exposure is associated with differences in cognitive performance, language development, motor skills, attention, and behavior as children grow. Attention deficit hyperactivity disorder emerges repeatedly in this literature as an outcome of concern, alongside broader questions about school readiness and executive function. The review’s authors are careful to note that isolating the effect of opioids from the confounding factors that travel with them, including prenatal exposure to other substances, maternal stress, poverty, and disrupted caregiving, remains a persistent methodological challenge. Still, the convergence of findings across multiple independent reviews supports the conclusion that opioid exposure can leave developmental traces that persist well past infancy.

The third and fourth domains extend the analysis beyond the exposed child to the family system. Psychosocial outcomes documented in the reviews include elevated risks for mental health difficulties, challenges with emotional regulation, and social adversity among children affected by their own exposure or by parental opioid misuse. Caregiving disruptions, meanwhile, capture a quieter but potentially profound harm: children whose parents struggle with opioid use disorder may experience instability in daily routines, foster care placement, kinship care arrangements, or the loss of a parent to overdose or incarceration. The umbrella review emphasizes that these indirect effects, transmitted through caregivers rather than through pharmacologic exposure, have received far less research attention than prenatal exposure, even though they affect a population that is at least as large.

That gap in the evidence is one of the review’s central messages. Effects were most extensively documented in infants with prenatal exposure, while research on parental opioid misuse affecting children, and on opioid misuse among adolescents and emerging adults themselves, remains comparatively thin. This is a striking asymmetry given that adolescents and young adults ages roughly 15 to 24 are among the groups at rising risk of initiating opioid misuse and developing opioid use disorder. The review explicitly flags adolescents and emerging adults as priority populations for future investigation, arguing that without better evidence, interventions and policies for these age groups will rest on extrapolation rather than on solid data.

Perhaps the most conceptually important finding concerns moderation. Across the synthesized literature, environmental factors, particularly socioeconomic status and the quality of caregiving, emerged as significant moderators of outcomes. In plain terms, the same pharmacologic exposure can lead to markedly different developmental trajectories depending on the resources, stability, and responsiveness of the child’s environment. This reframes opioid exposure not as biological destiny but as one risk operating within a web of protective and aggravating factors. It also offers a measure of hope: environments can be changed. Stable housing, responsive parenting support, early educational enrichment, and economic assistance are all modifiable, and the review’s findings suggest they may meaningfully alter the long-term outlook for affected children.

The authors translate this into a call for comprehensive early intervention that spans healthcare, education, and social services rather than treating opioid-related pediatric harm as a purely medical problem. For infants with neonatal opioid withdrawal syndrome, that means continued investment in evidence-based treatment and developmental follow-up. For young children affected by parental substance use, it means supporting caregivers through medications for opioid use disorder and family-centered services that keep families together when safe and possible. For adolescents, it means prevention and treatment systems designed for their developmental stage. The interconnected nature of the harms documented in the review, the authors argue, demands a correspondingly interconnected response, one that a single clinic or program cannot deliver alone.

Published as an open-access article with a permanent DOI, the review arrives at a moment when the crisis continues to evolve, with synthetic opioids reshaping exposure patterns in ways the included literature only partially captures. Its funding came from the William T. Grant Foundation, whose support runs through 2028, reflecting a funder focus on youth wellbeing. As a synthesis of syntheses, the paper does not offer a single headline statistic, and its authors would be the first to acknowledge that the quality of the underlying evidence averages barely above the midpoint of the assessment scale. What it does offer is a structured, honest account of how opioid misuse reverberates from the prenatal period through emerging adulthood, where the evidence is strong, where it is fragile, and where the next decade of research must go if children affected by the crisis are to receive interventions grounded in evidence rather than assumption.

Subject of Research: The effects of opioid misuse on fetal development, infants, children, adolescents, and emerging adults

Article Title: The impact of opioid misuse on fetal and pediatric populations: a systematic umbrella review

Article References: Barcenas, L. K., Kaz, L., Frerichs, L., & Hassmiller-Lich, K. (2026). The impact of opioid misuse on fetal and pediatric populations: a systematic umbrella review. Addiction Science & Clinical Practice. https://doi.org/10.1186/s13722-026-00715-w

Image Credits: AI Generated

DOI: 10.1186/s13722-026-00715-w

Keywords: opioid epidemic, pediatrics, fetal development, neonatal abstinence syndrome, neonatal opioid withdrawal syndrome, neurodevelopment, mental health, parental opioid misuse, caregiving disruption, umbrella review, early intervention, adolescent health

The research, led by Jamie L. Humphrey of RTI International together with Jason Williams, Sofia A. Oviedo, Bradley R. Ray, and Jessica D. Cance, addresses a question that has lingered as the synthetic opioid crisis deepened. Fentanyl and its analogs have driven unprecedented overdose mortality in the United States, but their effects extend beyond fatal poisoning. The drug’s extreme potency and rapid onset have altered injection frequency and syringe-sharing behavior in ways that heighten the risk of HIV transmission, and clusters of new infections in several states have underscored the urgency of embedding HIV testing, prevention, and treatment within settings where people who use drugs already seek care.

Integrated HIV services within substance use disorder treatment facilities have long been viewed as a critical intervention point for this syndemic of addiction, overdose, and infectious disease. Whether such services actually proliferated as fentanyl spread geographically, however, remained unknown. To find out, the research team assembled a longitudinal dataset of United States counties from 2015 through 2023, relying on geocoded facility listings from the National Survey of Substance Abuse Treatment Services and its successor, the National Substance Use and Mental Health Services Survey. The outcome of interest was the annual county-level proportion of substance use disorder treatment facilities reporting that they provided HIV services.

A central methodological challenge was defining when the fentanyl era began for any given county. Rather than relying on a single national date, the investigators derived state-specific onset points for rapid illicit fentanyl market penetration using data from the National Forensic Laboratory Information System, which tracks drug submissions to forensic laboratories across the country. This allowed the team to model each county’s trajectory of HIV service availability before and after the moment fentanyl effectively took over the local illicit drug supply, capturing the staggered diffusion of the synthetic opioid wave as it moved across the country.

The statistical approach was equally refined. The researchers employed longitudinal growth models with a beta distribution, a technique suited to modeling proportions bounded between zero and one, to estimate rates of change in HIV service availability across the study period. The models incorporated a set of time-varying covariates designed to isolate the effect of fentanyl’s arrival from other concurrent forces: county-level drug overdose mortality and HIV incidence rates, each lagged by two years to reflect plausible causal timing, as well as state-level policy factors including Medicaid expansion and prohibitions on prior authorization requirements for medications for opioid use disorder.

The headline result is striking in its simplicity. Between 2015 and 2023, the average proportion of substance use disorder treatment facilities providing HIV services doubled among counties that had treatment infrastructure in place. This was not a uniform trend, however. The geographic heterogeneity was considerable: following the introduction of fentanyl, HIV service availability increased in 38.8 percent of counties, remained stable in 14.0 percent, and decreased in 24.5 percent. Perhaps most sobering, 22.7 percent of counties had no measurable HIV service availability at all during the period because they lacked substance use disorder treatment facilities entirely, leaving residents of those areas without any local point of access to integrated care.

The adjusted models sharpened the temporal story. Before fentanyl’s arrival, the increase in HIV service provision within counties was modest and not statistically significant, with an estimated slope of 0.021 and a standard error of 0.013. After fentanyl was detected in a state’s drug market, integration accelerated markedly, with a post-fentanyl slope of 0.072 and a standard error of 0.009, a difference that was highly significant at P less than .001. A formal test of the interaction between the slope and fentanyl’s introduction confirmed that the acceleration was genuinely tied to the synthetic opioid’s arrival, with an interaction coefficient of 0.051 and a standard error of 0.014, also significant at P less than .001.

What these coefficients imply, in practical terms, is that the arrival of fentanyl appears to have functioned as a shock to the addiction treatment system, prompting facilities to adapt their service portfolios in response to a visibly escalating threat. The authors interpret this pattern as evidence of adaptive integration of HIV prevention and care within addiction treatment systems during the fentanyl era. Treatment organizations, confronting a drug supply that dramatically raised both overdose risk and injection-related HIV vulnerability, appear to have recognized that testing for HIV, linking patients to antiretroviral care, and offering preventive services were no longer optional adjuncts but core components of responsible care for a population facing compounded dangers.

Yet the study’s darker findings demand equal attention. Nearly one-quarter of United States counties had no in-person substance use disorder treatment infrastructure at all during the study window, a persistent service desert that no amount of integration within existing facilities can remedy. Moreover, even among counties with treatment capacity, the post-fentanyl period saw service availability decline in roughly one in four, indicating that the adaptive response was far from universal. Geographic disparities in access to integrated HIV and addiction services remain substantial, and the counties most vulnerable to overlapping overdose and HIV epidemics are often precisely those least equipped to respond.

The authors conclude that these patterns underscore the need for policies that expand substance use disorder treatment capacity and actively incentivize HIV service integration in underserved communities. As fentanyl, and increasingly its more potent analogs, continues to dominate the illicit drug supply, the window for preventive action narrows in the places least served. The research, which was supported by the National Institute on Drug Abuse under Award Number U24DA057611 and reviewed by the RTI International Institutional Review Board under protocol STUDY00022322, provides both a benchmark and a warning: the treatment system can respond to crisis, but only where treatment exists, and only when policy deliberately directs resources toward the communities where the syndemic burns hottest.

Subject of Research: Longitudinal county-level analysis of HIV service availability in US substance use disorder treatment facilities before and after the state-specific arrival of illicit fentanyl, 2015 to 2023.

Article Title: HIV service integration in substance use treatment facilities in the fentanyl era, 2015–2023

Article References: HIV service integration in substance use treatment facilities in the fentanyl era, 2015–2023. (n.d.). https://doi.org/10.1186/s12889-026-29460-0

Image Credits: AI Generated

DOI: 10.1186/s12889-026-29460-0

Keywords: HIV services, fentanyl, substance use disorder treatment, integrated care, overdose crisis, health services accessibility, geospatial analysis, HIV prevention, Medicaid expansion, opioid epidemic, public health, service integration